Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Carboplatin"" wg kryterium: Temat


Tytuł :
A multi-institutional randomized phase III study comparing weekly carboplatin plus nab-paclitaxel and daily low-dose carboplatin as regimens for concurrent chemoradiotherapy in elderly patients with unresectable locally advanced non-small cell lung cancer: Japan Clinical Oncology Group Study JCOG1914.
Autorzy :
Shimoyama R; JCOG Data Center/Operations Office, National Cancer Center Hospital, Tokyo, Japan.
Omori S; Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan.
Nomura S; JCOG Data Center/Operations Office, National Cancer Center Hospital, Tokyo, Japan.
Kenmotsu H; Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan.
Takahashi T; Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan.
Harada H; Radiation and Proton Therapy Center, Shizuoka Cancer Center, Shizuoka, Japan.
Ishikura S; Department of Radiology, Nagoya City University Graduate School of Medical Sciences, Aichi, Japan.
Mizutani T; Department of Medical Oncology, Kyorin University Faculty of Medicine, Tokyo, Japan.
Ando M; Department of Advanced Medicine, Nagoya University Hospital, Aichi, Japan.
Kataoka T; JCOG Data Center/Operations Office, National Cancer Center Hospital, Tokyo, Japan.
Fukuda H; JCOG Data Center/Operations Office, National Cancer Center Hospital, Tokyo, Japan.
Ohe Y; Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan.
Pokaż więcej
Corporate Authors :
Lung Cancer Study Group in the Japan Clinical Oncology Group
Źródło :
Japanese journal of clinical oncology [Jpn J Clin Oncol] 2021 Apr 30; Vol. 51 (5), pp. 836-841.
Typ publikacji :
Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial
MeSH Terms :
Albumins/*therapeutic use
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Carboplatin/*therapeutic use
Carcinoma, Non-Small-Cell Lung/*drug therapy
Chemoradiotherapy/*methods
Lung Neoplasms/*drug therapy
Paclitaxel/*therapeutic use
Aged ; Albumins/pharmacology ; Antineoplastic Combined Chemotherapy Protocols/pharmacology ; Carboplatin/administration & dosage ; Carboplatin/pharmacology ; Carcinoma, Non-Small-Cell Lung/pathology ; Female ; Humans ; Japan ; Lung Neoplasms/pathology ; Male ; Paclitaxel/pharmacology
Czasopismo naukowe
Tytuł :
The Affinity of Carboplatin to B-Vitamins and Nucleobases.
Autorzy :
Szefler B; Department of Physical Chemistry, Faculty of Pharmacy, Collegium Medicum, Nicolaus Copernicus University, Kurpińskiego 5, 85-096 Bydgoszcz, Poland.
Czeleń P; Department of Physical Chemistry, Faculty of Pharmacy, Collegium Medicum, Nicolaus Copernicus University, Kurpińskiego 5, 85-096 Bydgoszcz, Poland.
Krawczyk P; Department of Physical Chemistry, Faculty of Pharmacy, Collegium Medicum, Nicolaus Copernicus University, Kurpińskiego 5, 85-096 Bydgoszcz, Poland.
Pokaż więcej
Źródło :
International journal of molecular sciences [Int J Mol Sci] 2021 Mar 31; Vol. 22 (7). Date of Electronic Publication: 2021 Mar 31.
Typ publikacji :
Journal Article
MeSH Terms :
Carboplatin/*chemistry
Nucleotides/*chemistry
Vitamin B Complex/*chemistry
Antineoplastic Agents/therapeutic use ; Carboplatin/therapeutic use ; Humans ; Neoplasms/drug therapy ; Nucleotides/metabolism ; Pyridoxal Phosphate ; Riboflavin ; Thiamine ; Vitamin A ; Vitamin B 6/chemistry ; Vitamin B Complex/therapeutic use
Czasopismo naukowe
Tytuł :
A prospective audit on the use of prophylactic antiemetics and rates of CINV in patients receiving carboplatin AUC≥4 or combination anthracycline-cyclophosphamide.
Autorzy :
Lo E; Phase 1/Lung Research Fellow, Auckland Cancer Trials Centre, Auckland District Health Board.
Anderson M; Regional Cancer Treatment Service, MidCentral District Health Board.
Carroll R; Regional Cancer Treatment Service, MidCentral District Health Board.
Forgeson G; Regional Cancer Treatment Service, MidCentral District Health Board.
Isaacs R; Regional Cancer Treatment Service, MidCentral District Health Board.
Jordan J; Regional Cancer Treatment Service, Hawke's Bay District Health Board.
Satterthwaite L; Regional Cancer Treatment Service, MidCentral District Health Board.
Wewala N; Regional Cancer Treatment Service, MidCentral District Health Board.
Fernando J; Regional Cancer Treatment Service, MidCentral District Health Board.
Pokaż więcej
Źródło :
The New Zealand medical journal [N Z Med J] 2021 Apr 16; Vol. 134 (1533), pp. 33-45. Date of Electronic Publication: 2021 Apr 16.
Typ publikacji :
Journal Article
MeSH Terms :
Anthracyclines/*adverse effects
Antiemetics/*therapeutic use
Antineoplastic Combined Chemotherapy Protocols/*adverse effects
Carboplatin/*adverse effects
Cyclophosphamide/*adverse effects
Nausea/*prevention & control
Vomiting/*prevention & control
Adult ; Aged ; Aged, 80 and over ; Anthracyclines/pharmacokinetics ; Antineoplastic Combined Chemotherapy Protocols/pharmacokinetics ; Area Under Curve ; Carboplatin/pharmacokinetics ; Cyclophosphamide/pharmacokinetics ; Female ; Humans ; Male ; Medical Audit ; Middle Aged ; Prospective Studies
Czasopismo naukowe
Tytuł :
Anti-tumor effects and cell motility inhibition of the DN604-gemcitabine combined treatment in human bladder cancer models.
Autorzy :
Wang X; Pharmaceutical Research Center and School of Chemistry and Chemical Engineering, Southeast University, Nanjing 211189, China.
Chen F; Pharmaceutical Research Center and School of Chemistry and Chemical Engineering, Southeast University, Nanjing 211189, China; Jiangsu Province Hi-Tech Key Laboratory for Biomedical Research, Southeast University, Nanjing 211189, China.
Gou S; Pharmaceutical Research Center and School of Chemistry and Chemical Engineering, Southeast University, Nanjing 211189, China; Jiangsu Province Hi-Tech Key Laboratory for Biomedical Research, Southeast University, Nanjing 211189, China. Electronic address: .
Pokaż więcej
Źródło :
Bioorganic & medicinal chemistry [Bioorg Med Chem] 2021 Jan 01; Vol. 29, pp. 115858. Date of Electronic Publication: 2020 Nov 07.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Antineoplastic Combined Chemotherapy Protocols/*pharmacology
Carboplatin/*analogs & derivatives
Deoxycytidine/*analogs & derivatives
Urinary Bladder Neoplasms/*drug therapy
Animals ; Antineoplastic Combined Chemotherapy Protocols/chemical synthesis ; Antineoplastic Combined Chemotherapy Protocols/chemistry ; Apoptosis/drug effects ; Carboplatin/chemistry ; Carboplatin/pharmacology ; Cell Movement/drug effects ; Cell Proliferation/drug effects ; Deoxycytidine/chemistry ; Deoxycytidine/pharmacology ; Dose-Response Relationship, Drug ; Drug Screening Assays, Antitumor ; Humans ; Mice ; Mice, Inbred BALB C ; Mice, Nude ; Molecular Structure ; Neoplasms, Experimental/drug therapy ; Neoplasms, Experimental/metabolism ; Neoplasms, Experimental/pathology ; Structure-Activity Relationship ; Tumor Cells, Cultured ; Urinary Bladder Neoplasms/metabolism ; Urinary Bladder Neoplasms/pathology
Czasopismo naukowe
Tytuł :
Carboplatin re-treatment in platinum-resistant epithelial ovarian cancer patients.
Autorzy :
Hansen MKG; Department of Oncology, Lillebaelt Hospital - University Hospital of Southern Denmark,, Beriderbakken 4, 7100, Vejle, Denmark. .
Smerdel MP; Department of Clinical Genetics, Lillebaelt Hospital - University Hospital of Southern Denmark, Beriderbakken 4, 7100, Vejle, Denmark.
Waldstrøm M; Department of Pathology, Lillebaelt Hospital - University Hospital of Southern Denmark, Beriderbakken 4, 7100, Vejle, Denmark.
Andersen RF; Department of Clinical Biochemistry, Lillebaelt Hospital - University Hospital of Southern Denmark, Beriderbakken 4, 7100, Vejle, Denmark.
Adimi P; Department of Oncology, Lillebaelt Hospital - University Hospital of Southern Denmark,, Beriderbakken 4, 7100, Vejle, Denmark.
Jakobsen A; Department of Oncology, Lillebaelt Hospital - University Hospital of Southern Denmark,, Beriderbakken 4, 7100, Vejle, Denmark.
Steffensen KD; Department of Oncology, Lillebaelt Hospital - University Hospital of Southern Denmark,, Beriderbakken 4, 7100, Vejle, Denmark.
Pokaż więcej
Źródło :
Cancer chemotherapy and pharmacology [Cancer Chemother Pharmacol] 2020 Dec; Vol. 86 (6), pp. 751-759. Date of Electronic Publication: 2020 Oct 16.
Typ publikacji :
Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Antineoplastic Combined Chemotherapy Protocols/*administration & dosage
Carboplatin/*administration & dosage
Carcinoma, Ovarian Epithelial/*therapy
Ovarian Neoplasms/*therapy
Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Bevacizumab/administration & dosage ; Bevacizumab/adverse effects ; Biomarkers, Tumor/blood ; Carboplatin/adverse effects ; Carcinoma, Ovarian Epithelial/blood ; Carcinoma, Ovarian Epithelial/mortality ; Carcinoma, Ovarian Epithelial/pathology ; Cell-Free Nucleic Acids/blood ; Chemotherapy, Adjuvant/methods ; Chemotherapy, Adjuvant/statistics & numerical data ; Cytoreduction Surgical Procedures ; Drug Monitoring/methods ; Drug Resistance, Neoplasm ; Feasibility Studies ; Female ; Humans ; Middle Aged ; Ovarian Neoplasms/blood ; Ovarian Neoplasms/mortality ; Ovarian Neoplasms/pathology ; Prognosis ; Progression-Free Survival ; Prospective Studies ; Response Evaluation Criteria in Solid Tumors ; Retreatment/methods ; Retreatment/statistics & numerical data
Czasopismo naukowe
Tytuł :
Objective responses to first-line neoadjuvant carboplatin-paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial.
Autorzy :
Morgan RD; The Christie NHS Foundation Trust and University of Manchester, Manchester, UK.
McNeish IA; Ovarian Cancer Action Research Centre, Department of Surgery and Cancer, Imperial College London, London, UK.
Cook AD; Medical Research Council Clinical Trials Unit, Institute of Clinical Trials and Methodology, University College London, London, UK.
James EC; Medical Research Council Clinical Trials Unit, Institute of Clinical Trials and Methodology, University College London, London, UK.
Lord R; The Clatterbridge Cancer Centre NHS Foundation Trust, Bebington, UK.
Dark G; The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.
Glasspool RM; Beatson West of Scotland Cancer Centre, Glasgow, UK.
Krell J; Ovarian Cancer Action Research Centre, Department of Surgery and Cancer, Imperial College London, London, UK.
Parkinson C; Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
Poole CJ; Arden Cancer Research Centre, University Hospital Coventry and Warwickshire NHS Trust, Coventry, UK.
Hall M; Mount Vernon Cancer Centre, Northwood, UK.
Gallardo-Rincón D; Instituto Nacional de Cancerología, Mexico City, Mexico.
Lockley M; St Bartholomew's Hospital, Barts Health NHS Trust, London, UK.
Essapen S; Royal Surrey NHS Foundation Trust, Guildford, UK.
Summers J; Maidstone and Tunbridge Wells NHS Trust, Kent, UK.
Anand A; Nottingham University Hospitals NHS Trust, Nottingham, UK.
Zachariah A; Shrewsbury and Telford Hospital NHS Trust, Shrewsbury, UK.
Williams S; University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
Jones R; South West Wales Cancer Centre, Singleton Hospital, Swansea, UK.
Scatchard K; Royal Devon and Exeter NHS Foundation Trust, Exeter, UK.
Walther A; University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, UK.
Kim JW; Seoul National University College of Medicine, Seoul, South Korea.
Sundar S; Pan Birmingham Gynaecological Cancer Centre and University of Birmingham, Birmingham, UK.
Jayson GC; The Christie NHS Foundation Trust and University of Manchester, Manchester, UK.
Ledermann JA; UCL Hospitals NHS Foundation Trust and UCL Cancer Institute, London, UK.
Clamp AR; The Christie NHS Foundation Trust and University of Manchester, Manchester, UK. Electronic address: .
Pokaż więcej
Źródło :
The Lancet. Oncology [Lancet Oncol] 2021 Feb; Vol. 22 (2), pp. 277-288. Date of Electronic Publication: 2020 Dec 22.
Typ publikacji :
Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Carboplatin/*administration & dosage
Fallopian Tube Neoplasms/*drug therapy
Ovarian Neoplasms/*drug therapy
Paclitaxel/*administration & dosage
Peritoneal Neoplasms/*drug therapy
Aged ; Australia ; CA-125 Antigen ; Carboplatin/adverse effects ; Disease-Free Survival ; Fallopian Tube Neoplasms/genetics ; Fallopian Tube Neoplasms/pathology ; Fallopian Tubes/pathology ; Female ; Humans ; Ireland ; Membrane Proteins ; Middle Aged ; Neoadjuvant Therapy/adverse effects ; New Zealand ; Ovarian Neoplasms/genetics ; Ovarian Neoplasms/pathology ; Paclitaxel/adverse effects ; Peritoneal Neoplasms/genetics ; Peritoneal Neoplasms/pathology ; Response Evaluation Criteria in Solid Tumors
Czasopismo naukowe
Tytuł :
Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial.
Autorzy :
Pignata S; Dipartimento Urogenitale, Istituto Nazionale per lo Studio e la Cura dei Tumori IRCCS Fondazione Pascale, Naples, Italy. Electronic address: .
Lorusso D; Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy; Dipartimento di Chirurgia, SC Chirurgia Ginecologica, Fondazione IRCCS Istituto Nazionale Tumori di Milano, Milan, Italy.
Joly F; Département recherche, enseignement, innovation, Centre François Baclesse, Caen, France; Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens, Paris, France.
Gallo C; Dipartimento di Salute Mentale Fisica e Medicina Preventiva, Università degli Studi della Campania Luigi Vanvitelli, Naples, Italy.
Colombo N; Istituto Europeo di Oncologia IRCCS, Milan, Italy; Dipartimento di Medicina e Chirurgia, Università degli Studi di Milano-Bicocca, Milan, Italy.
Sessa C; Unità tumori ginecologici, Istituto Oncologico della Svizzera Italiana, Bellinzona, Switzerland.
Bamias A; Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Athens, Greece.
Salutari V; Dipartimento di Scienze della Salute della Donna, del Bambino e di Sanità Pubblica, Ginecologia Oncologica-Fondazione Policlinico Universitario Gemelli, Università Cattolica del Sacro Cuore di Roma, Rome, Italy.
Selle F; Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens, Paris, France; Service Oncologie, Groupe Hospitalier Diaconesses Croix Saint-Simon, Paris, France.
Frezzini S; Oncologia Medica II, Istituto Oncologico Veneto IRCCS, Padua, Italy; Dipartimento di Oncologia, University of Padova, Padua, Italy.
De Giorgi U; Oncologia Medica, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori IRCCS, Meldola, Italy.
Pautier P; Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens, Paris, France; Department de Medecine, Institut Gustave Roussy, Université Paris Saclay, Villejuif, France.
Bologna A; Oncologia, Azienda Unità Sanitaria Locale di Reggio Emilia-IRCCS, Reggio Emilia, Italy.
Orditura M; Dipartimento DAI di Internistica Polispecialistica-Oncologia Medica ed Ematologia, Azienda Ospedaliera Universitaria, Università degli Studi della Campania Luigi Vanvitelli, Naples, Italy.
Dubot C; Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens, Paris, France; Oncologie Médicale, Institut Curie Saint-Cloud, Saint-Cloud, France.
Gadducci A; Dipartimento di Medicina Clinica e Sperimentale, UO Ginecologia e Ostetricia, Università di Pisa, Pisa, Italy.
Mammoliti S; Oncologia Medica 1, IRCCS San Martino IST, Genova, Italy.
Ray-Coquard I; Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens, Paris, France; Département d'Oncologie Médicale, Centre Léon Bérard, Lyon, France.
Zafarana E; Dipartimento Oncologico, SOC Oncologia Medica-Prato, Nuovo Ospedale di Prato Santo Stefano, Azienda USL Toscana Centro, Prato, Italy.
Breda E; Dipartimento di Oncologia, Ospedale San Giovanni Calibita Fatebenefratelli, Rome, Italy.
Favier L; Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens, Paris, France; Service d'oncologie médicale, L'HôpitalPrivé du Confluent, Nantes, France.
Ardizzoia A; Dipartimento Oncologico, Ospedale Alessandro Manzoni-ASST Lecco, Lecco, Italy.
Cinieri S; Oncologia Medica-Ospedale Senatore Antonio Perrino, Brindisi, Italy.
Largillier R; Centre Azuréen de Cancérologie, Mougins, France.
Sambataro D; Oncologia Medica, A O Garibaldi-Nesima, Catania, Italy.
Guardiola E; Service d'oncologie médicale-hématologie, Centre Hospitalier de la Dracénie, Draguignan, France.
Lauria R; Dipartimento DAI di Oncoematologia, Diagnostica per Immagini e Morfologica e Medicina Legale, Oncologia Medica-Azienda Ospedaliera Universitaria Policlinico Universitario Federico II, Naples, Italy.
Pisano C; Dipartimento Urogenitale, Istituto Nazionale per lo Studio e la Cura dei Tumori IRCCS Fondazione Pascale, Naples, Italy.
Raspagliesi F; Dipartimento di Chirurgia, SC Chirurgia Ginecologica, Fondazione IRCCS Istituto Nazionale Tumori di Milano, Milan, Italy.
Scambia G; Dipartimento di Scienze della Salute della Donna, del Bambino e di Sanità Pubblica, Ginecologia Oncologica-Fondazione Policlinico Universitario Gemelli, Università Cattolica del Sacro Cuore di Roma, Rome, Italy.
Daniele G; Dipartimento di Ricerca Traslazionale, Istituto Nazionale per lo Studio e la Cura dei Tumori IRCCS Fondazione Pascale, Naples, Italy; Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.
Perrone F; Dipartimento di Ricerca Traslazionale, Istituto Nazionale per lo Studio e la Cura dei Tumori IRCCS Fondazione Pascale, Naples, Italy.
Pokaż więcej
Corporate Authors :
MITO16b/MANGO–OV2/ENGOT–ov17 Investigators
Źródło :
The Lancet. Oncology [Lancet Oncol] 2021 Feb; Vol. 22 (2), pp. 267-276.
Typ publikacji :
Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Antineoplastic Combined Chemotherapy Protocols/*administration & dosage
Bevacizumab/*administration & dosage
Carboplatin/*administration & dosage
Ovarian Neoplasms/*drug therapy
Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Bevacizumab/adverse effects ; Carboplatin/adverse effects ; Disease Progression ; Disease-Free Survival ; Doxorubicin/administration & dosage ; Doxorubicin/analogs & derivatives ; Drug Resistance, Neoplasm ; Female ; Humans ; Middle Aged ; Neoplasm Recurrence, Local ; Ovarian Neoplasms/pathology ; Paclitaxel/administration & dosage ; Polyethylene Glycols/administration & dosage
Czasopismo naukowe
Tytuł :
Results from a biomarker study to accompany a phase II trial of RRx-001 with reintroduced platinum-based chemotherapy in relapsed small cell carcinoma.
Autorzy :
Lee MJ; Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute (NCI), National Institutes of Health (NIH) , Bethesda, MD, USA.
Tomita Y; Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute (NCI), National Institutes of Health (NIH) , Bethesda, MD, USA.
Yuno A; Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute (NCI), National Institutes of Health (NIH) , Bethesda, MD, USA.
Lee S; Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute (NCI), National Institutes of Health (NIH) , Bethesda, MD, USA.
Abrouk NE; Department of Clinical Research, Clinical Trial Innovations , Mountain View, CA, USA.
Oronsky B; Department of Clinical Research, EpicentRx, Inc , La Jolla, CA, USA.
Caroen S; Department of Clinical Research, EpicentRx, Inc , La Jolla, CA, USA.
Trepel JB; Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute (NCI), National Institutes of Health (NIH) , Bethesda, MD, USA.
Pokaż więcej
Źródło :
Expert opinion on investigational drugs [Expert Opin Investig Drugs] 2021 Feb; Vol. 30 (2), pp. 177-183. Date of Electronic Publication: 2021 Jan 11.
Typ publikacji :
Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial
MeSH Terms :
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Azetidines/*therapeutic use
Carboplatin/*therapeutic use
Cisplatin/*therapeutic use
Etoposide/*therapeutic use
Lung Neoplasms/*drug therapy
Nitro Compounds/*therapeutic use
Small Cell Lung Carcinoma/*drug therapy
Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Azetidines/adverse effects ; Carboplatin/adverse effects ; Cisplatin/adverse effects ; Disease Progression ; Etoposide/adverse effects ; HLA-DR Antigens/blood ; Humans ; Lung Neoplasms/blood ; Lung Neoplasms/mortality ; Lung Neoplasms/pathology ; Membrane Glycoproteins/blood ; Nitro Compounds/adverse effects ; Receptors, Immunologic/blood ; Small Cell Lung Carcinoma/blood ; Small Cell Lung Carcinoma/mortality ; Small Cell Lung Carcinoma/pathology ; Time Factors ; Treatment Outcome ; Tumor-Associated Macrophages/drug effects ; Tumor-Associated Macrophages/metabolism
Czasopismo naukowe
Tytuł :
An Open-Label Randomized Controlled Trial Comparing the Efficacy and Safety of Pemetrexed-Carboplatin versus (Weekly) Paclitaxel-Carboplatin as First-Line Chemotherapy in Advanced Non-Squamous Non-Small Cell Lung Cancer.
Autorzy :
Yadav A; Department of Medical Oncology, Dr. BRAIRCH, All India Institute of Medical Sciences, New Delhi, India.
Malik PS; Department of Medical Oncology, Dr. BRAIRCH, All India Institute of Medical Sciences, New Delhi, India, .
Khurana S; Department of Medical Oncology, Dr. BRAIRCH, All India Institute of Medical Sciences, New Delhi, India.
Jain D; Department of Pathology, All India Institute of Medical Sciences, New Delhi, India.
Vishnubhatla S; Department of Biostatistics, All India Institute of Medical Sciences, New Delhi, India.
Yadav M; Department of Radiology, Dr. BRAIRCH, All India Institute of Medical Sciences, New Delhi, India.
Pathy S; Department of Radiation Oncology, Dr. BRAIRCH, All India Institute of Medical Sciences, New Delhi, India.
Mohan A; Department of Pulmonary, Critical Care and Sleep Medicine, All India Institute of Medical Sciences, New Delhi, India.
Kumar L; Department of Medical Oncology, Dr. BRAIRCH, All India Institute of Medical Sciences, New Delhi, India.
Pokaż więcej
Źródło :
Oncology [Oncology] 2021; Vol. 99 (6), pp. 389-396. Date of Electronic Publication: 2021 Mar 18.
Typ publikacji :
Comparative Study; Equivalence Trial; Journal Article; Randomized Controlled Trial
MeSH Terms :
Antineoplastic Combined Chemotherapy Protocols/*administration & dosage
Carboplatin/*administration & dosage
Carcinoma, Non-Small-Cell Lung/*drug therapy
Lung Neoplasms/*drug therapy
Paclitaxel/*administration & dosage
Pemetrexed/*administration & dosage
Academic Medical Centers ; Adult ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Carboplatin/adverse effects ; Drug Administration Schedule ; Female ; Humans ; India ; Male ; Middle Aged ; Paclitaxel/adverse effects ; Pemetrexed/adverse effects ; Survival Analysis ; Tertiary Care Centers ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial.
Autorzy :
Goldman JW; David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA, USA.
Dvorkin M; BHI of Omsk Region Clinical Oncology Dispensary, Omsk, Russia.
Chen Y; Cancer and Hematology Centers of Western Michigan, Grand Rapids, MI, USA.
Reinmuth N; Asklepios Lung Clinic, Munich-Gauting, Germany.
Hotta K; Okayama University Hospital, Okayama, Japan.
Trukhin D; Odessa Regional Oncological Dispensary, Odessa, Ukraine.
Statsenko G; Omsk Regional Cancer Centre, Omsk, Russia.
Hochmair MJ; Karl Landsteiner Institute of Lung Research and Pulmonary Oncology, Klinik Floridsdorf, Vienna, Austria.
Özgüroğlu M; Istanbul University-Cerrahpaşa, Cerrahpaşa School of Medicine, Istanbul, Turkey.
Ji JH; Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon, South Korea.
Garassino MC; Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Voitko O; Kyiv City Clinical Oncological Centre, Kiev, Ukraine.
Poltoratskiy A; Petrov Research Institute of Oncology, St Petersburg, Russia.
Ponce S; Department of Medical Oncology, Hospital Universitario 12 de Octubre, H120-CNIO Lung Cancer Unit, Universidad Complutense and Ciberonc, Madrid, Spain.
Verderame F; Azienda Ospedaliera Ospedali Riuniti PO Vincenzo Cervello, Palermo, Italy.
Havel L; Thomayer Hospital, First Faculty of Medicine, Charles University, Prague, Czech Republic.
Bondarenko I; Dnipropetrovsk Medical Academy, Dnipro, Ukraine.
Każarnowicz A; Tuberculosis and Lung Disease Hospital, Olsztyn, Poland.
Losonczy G; Department of Pulmonology, Semmelweis University, Budapest, Hungary.
Conev NV; Clinic of Medical Oncology, University Multiprofile Hospital for Active Treatment St Marina, Varna, Bulgaria.
Armstrong J; AstraZeneca, Cambridge, UK.
Byrne N; AstraZeneca, Cambridge, UK.
Thiyagarajah P; AstraZeneca, Cambridge, UK.
Jiang H; AstraZeneca, Gaithersburg, MD, USA.
Paz-Ares L; Department of Medical Oncology, Hospital Universitario 12 de Octubre, H120-CNIO Lung Cancer Unit, Universidad Complutense and Ciberonc, Madrid, Spain. Electronic address: .
Pokaż więcej
Corporate Authors :
CASPIAN investigators
Źródło :
The Lancet. Oncology [Lancet Oncol] 2021 Jan; Vol. 22 (1), pp. 51-65. Date of Electronic Publication: 2020 Dec 04.
Typ publikacji :
Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Antibodies, Monoclonal/*administration & dosage
Antibodies, Monoclonal, Humanized/*administration & dosage
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Carboplatin/*administration & dosage
Cisplatin/*administration & dosage
Etoposide/*administration & dosage
Lung Neoplasms/*drug therapy
Small Cell Lung Carcinoma/*drug therapy
Aged ; Antibodies, Monoclonal/adverse effects ; Antibodies, Monoclonal, Humanized/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Carboplatin/adverse effects ; Cisplatin/adverse effects ; Disease Progression ; Etoposide/adverse effects ; Female ; Humans ; Lung Neoplasms/mortality ; Lung Neoplasms/pathology ; Male ; Middle Aged ; Neoplasm Staging ; Progression-Free Survival ; Small Cell Lung Carcinoma/mortality ; Small Cell Lung Carcinoma/pathology ; Time Factors
Czasopismo naukowe
Tytuł :
Phase I trial of intracerebral convection-enhanced delivery of carboplatin for treatment of recurrent high-grade gliomas.
Autorzy :
Wang JL; Department of Neurological Surgery, The Ohio State University College of Medicine Wexner Medical Center, Columbus, Ohio, United States of America.
Barth RF; Department of Pathology, The Ohio State University College of Medicine Wexner Medical Center, Columbus, Ohio, United States of America.
Cavaliere R; Division of Neuro-Oncology, Department of Neurology, The Ohio State University College of Medicine Wexner Medical Center, Columbus, Ohio, United States of America.
Puduvalli VK; Division of Neuro-Oncology, Department of Neurology, The Ohio State University College of Medicine Wexner Medical Center, Columbus, Ohio, United States of America.
Giglio P; Division of Neuro-Oncology, Department of Neurology, The Ohio State University College of Medicine Wexner Medical Center, Columbus, Ohio, United States of America.
Lonser RR; Department of Neurological Surgery, The Ohio State University College of Medicine Wexner Medical Center, Columbus, Ohio, United States of America.
Elder JB; Department of Neurological Surgery, The Ohio State University College of Medicine Wexner Medical Center, Columbus, Ohio, United States of America.
Pokaż więcej
Źródło :
PloS one [PLoS One] 2020 Dec 29; Vol. 15 (12), pp. e0244383. Date of Electronic Publication: 2020 Dec 29 (Print Publication: 2020).
Typ publikacji :
Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Antineoplastic Agents/*administration & dosage
Brain Neoplasms/*therapy
Carboplatin/*administration & dosage
Glioma/*therapy
Oligodendroglioma/*therapy
Adult ; Antineoplastic Agents/therapeutic use ; Brain Neoplasms/diagnostic imaging ; Brain Neoplasms/pathology ; Carboplatin/therapeutic use ; Combined Modality Therapy ; Convection ; Feasibility Studies ; Female ; Glioma/diagnostic imaging ; Glioma/pathology ; Humans ; Injections, Intralesional/instrumentation ; Male ; Maximum Tolerated Dose ; Middle Aged ; Neoplasm Grading ; Oligodendroglioma/diagnostic imaging ; Oligodendroglioma/pathology ; Survival Analysis ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Cisplatin and carboplatin result in similar gonadotoxicity in immature human testis with implications for fertility preservation in childhood cancer.
Autorzy :
Tharmalingam MD; MRC Centre for Reproductive Health, The Queen's Medical Research Institute, The University of Edinburgh, 47 Little France Crescent, Edinburgh, EH16 4TJ, Scotland, UK.; KK Women's and Children's Hospital, Bukit Timah Rd, 100, Singapore, 229899, Singapore.
Matilionyte G; MRC Centre for Reproductive Health, The Queen's Medical Research Institute, The University of Edinburgh, 47 Little France Crescent, Edinburgh, EH16 4TJ, Scotland, UK.
Wallace WHB; Edinburgh Royal Hospital for Sick Children, 9 Sciennes Road, Edinburgh, EH9 1LF, Scotland, UK.
Stukenborg JB; NORDFERTIL Research Lab Stockholm, Childhood Cancer Research Unit, Department of Women's and Children's Health, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden.
Jahnukainen K; NORDFERTIL Research Lab Stockholm, Childhood Cancer Research Unit, Department of Women's and Children's Health, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden.; Division of Haematology-Oncology and Stem Cell Transplantation, Children's Hospital, University of Helsinki, Helsinki University Central Hospital, Helsinki, Finland.
Oliver E; NORDFERTIL Research Lab Stockholm, Childhood Cancer Research Unit, Department of Women's and Children's Health, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden.
Goriely A; Radcliffe Department of Medicine, MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, OX39DS, UK.
Lane S; Department of Paediatrics and Child Health, Oxford University Hospitals NHS Foundation Trust, and Nuffield Department of Womens and Reproductive Health, University of Oxford, Oxford, UK.
Guo J; Section of Andrology, Division of Urology, Department of Surgery, University of Utah School of Medicine, Salt Lake City, UT, USA.; Howard Hughes Medical Institute, Department of Oncological Sciences and Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, UT, USA.
Cairns B; Howard Hughes Medical Institute, Department of Oncological Sciences and Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, UT, USA.
Jorgensen A; Department of Growth and Reproduction, Copenhagen University Hospital (Rigshospitalet), Blegdamsvej 9, 2100, Copenhagen, Denmark.
Allen CM; Biomedical Sciences, University of Edinburgh, Edinburgh, EH8 9XD, UK.
Lopes F; MRC Centre for Reproductive Health, The Queen's Medical Research Institute, The University of Edinburgh, 47 Little France Crescent, Edinburgh, EH16 4TJ, Scotland, UK.
Anderson RA; MRC Centre for Reproductive Health, The Queen's Medical Research Institute, The University of Edinburgh, 47 Little France Crescent, Edinburgh, EH16 4TJ, Scotland, UK.
Spears N; Biomedical Sciences, University of Edinburgh, Edinburgh, EH8 9XD, UK.
Mitchell RT; MRC Centre for Reproductive Health, The Queen's Medical Research Institute, The University of Edinburgh, 47 Little France Crescent, Edinburgh, EH16 4TJ, Scotland, UK. .; Edinburgh Royal Hospital for Sick Children, 9 Sciennes Road, Edinburgh, EH9 1LF, Scotland, UK. .
Pokaż więcej
Źródło :
BMC medicine [BMC Med] 2020 Dec 04; Vol. 18 (1), pp. 374. Date of Electronic Publication: 2020 Dec 04.
Typ publikacji :
Case Reports; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Carboplatin/*adverse effects
Cisplatin/*adverse effects
Fertility Preservation/*methods
Neoplasms/*complications
Testis/*drug effects
Animals ; Carboplatin/pharmacology ; Child ; Cisplatin/pharmacology ; Humans ; Male ; Mice ; Neoplasms/drug therapy ; Xenograft Model Antitumor Assays
Czasopismo naukowe
Tytuł :
Synthesis and in vitro antitumour activity of carboplatin analogues containing functional handles compatible for conjugation to drug delivery systems.
Autorzy :
Rečnik LM; Institut des Biomolécules Max Mousseron, UMR 5247, CNRS, Université de Montpellier, ENSCM, UFR des Sciences Pharmaceutiques et Biologiques, 15 Avenue Charles Flahault, 34093 Montpellier Cedex 5, France; Institut de Recherche en Cancérologie de Montpellier, INSERM, Université de Montpellier, Institut Régional du Cancer de Montpellier, 208 Avenue des Apothicaires, 34298 Montpellier Cedex 5, France.
Cantelli C; Institut des Biomolécules Max Mousseron, UMR 5247, CNRS, Université de Montpellier, ENSCM, UFR des Sciences Pharmaceutiques et Biologiques, 15 Avenue Charles Flahault, 34093 Montpellier Cedex 5, France; Institut de Recherche en Cancérologie de Montpellier, INSERM, Université de Montpellier, Institut Régional du Cancer de Montpellier, 208 Avenue des Apothicaires, 34298 Montpellier Cedex 5, France.
Fersing C; Institut des Biomolécules Max Mousseron, UMR 5247, CNRS, Université de Montpellier, ENSCM, UFR des Sciences Pharmaceutiques et Biologiques, 15 Avenue Charles Flahault, 34093 Montpellier Cedex 5, France; Nuclear Medicine Department, Montpellier Cancer Institute (ICM), University of Montpellier, 208 Avenue des Apothicaires, 34298 Montpellier Cedex 5, France.
Gongora C; Institut de Recherche en Cancérologie de Montpellier, INSERM, Université de Montpellier, Institut Régional du Cancer de Montpellier, 208 Avenue des Apothicaires, 34298 Montpellier Cedex 5, France.
Pouget JP; Institut de Recherche en Cancérologie de Montpellier, INSERM, Université de Montpellier, Institut Régional du Cancer de Montpellier, 208 Avenue des Apothicaires, 34298 Montpellier Cedex 5, France.
Lisowski V; Institut des Biomolécules Max Mousseron, UMR 5247, CNRS, Université de Montpellier, ENSCM, UFR des Sciences Pharmaceutiques et Biologiques, 15 Avenue Charles Flahault, 34093 Montpellier Cedex 5, France. Electronic address: .
Pokaż więcej
Źródło :
Bioorganic & medicinal chemistry letters [Bioorg Med Chem Lett] 2020 Nov 15; Vol. 30 (22), pp. 127527. Date of Electronic Publication: 2020 Sep 02.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Drug Delivery Systems*
Antineoplastic Agents/*pharmacology
Carboplatin/*pharmacology
Antineoplastic Agents/chemical synthesis ; Antineoplastic Agents/chemistry ; Carboplatin/chemical synthesis ; Carboplatin/chemistry ; Cell Line, Tumor ; Cell Proliferation/drug effects ; Cell Survival/drug effects ; Dose-Response Relationship, Drug ; Drug Screening Assays, Antitumor ; Humans ; Molecular Structure ; Structure-Activity Relationship
Czasopismo naukowe
Tytuł :
Combination of DN604 with gemcitabine led to cell apoptosis and cell motility inhibition via p38 MAPK signaling pathway in NSCLC.
Autorzy :
Wang X; Pharmaceutical Research Center and School of Chemistry and Chemical Engineering, Southeast University, Nanjing 211189, China.
Chen F; Pharmaceutical Research Center and School of Chemistry and Chemical Engineering, Southeast University, Nanjing 211189, China; Jiangsu Province Hi-Tech Key Laboratory for Biomedical Research, Southeast University, Nanjing 211189, China. Electronic address: .
Gou S; Pharmaceutical Research Center and School of Chemistry and Chemical Engineering, Southeast University, Nanjing 211189, China; Jiangsu Province Hi-Tech Key Laboratory for Biomedical Research, Southeast University, Nanjing 211189, China. Electronic address: .
Pokaż więcej
Źródło :
Bioorganic chemistry [Bioorg Chem] 2020 Nov; Vol. 104, pp. 104234. Date of Electronic Publication: 2020 Aug 26.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Antineoplastic Agents/*pharmacology
Apoptosis/*drug effects
Carboplatin/*analogs & derivatives
Carcinoma, Non-Small-Cell Lung/*drug therapy
Deoxycytidine/*analogs & derivatives
Lung Neoplasms/*drug therapy
Protein Kinase Inhibitors/*pharmacology
p38 Mitogen-Activated Protein Kinases/*antagonists & inhibitors
Animals ; Antineoplastic Agents/chemical synthesis ; Antineoplastic Agents/chemistry ; Carboplatin/chemistry ; Carboplatin/pharmacology ; Carcinoma, Non-Small-Cell Lung/metabolism ; Carcinoma, Non-Small-Cell Lung/pathology ; Cell Movement/drug effects ; Cell Proliferation/drug effects ; Cell Survival/drug effects ; Deoxycytidine/chemistry ; Deoxycytidine/pharmacology ; Dose-Response Relationship, Drug ; Drug Screening Assays, Antitumor ; Humans ; Lung Neoplasms/metabolism ; Lung Neoplasms/pathology ; Mice ; Mice, Nude ; Molecular Structure ; Neoplasms, Experimental/drug therapy ; Neoplasms, Experimental/metabolism ; Neoplasms, Experimental/pathology ; Protein Kinase Inhibitors/chemical synthesis ; Protein Kinase Inhibitors/chemistry ; Signal Transduction/drug effects ; Structure-Activity Relationship ; Tumor Cells, Cultured ; p38 Mitogen-Activated Protein Kinases/metabolism
Czasopismo naukowe
Tytuł :
Evaluation of the pharmacokinetic drug-drug interaction potential of iohexol, a renal filtration marker.
Autorzy :
Joshi A; Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, PA, USA.
Guo J; Cancer Therapeutics Program, UPMC Hillman Cancer Center, Hillman Research Pavilion, Room G27E 5117 Centre Avenue, Pittsburgh, PA, 15213-1863, USA.
Holleran JL; Cancer Therapeutics Program, UPMC Hillman Cancer Center, Hillman Research Pavilion, Room G27E 5117 Centre Avenue, Pittsburgh, PA, 15213-1863, USA.
Kiesel B; Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, PA, USA.; Cancer Therapeutics Program, UPMC Hillman Cancer Center, Hillman Research Pavilion, Room G27E 5117 Centre Avenue, Pittsburgh, PA, 15213-1863, USA.
Taylor S; Cancer Therapeutics Program, UPMC Hillman Cancer Center, Hillman Research Pavilion, Room G27E 5117 Centre Avenue, Pittsburgh, PA, 15213-1863, USA.
Christner S; Cancer Therapeutics Program, UPMC Hillman Cancer Center, Hillman Research Pavilion, Room G27E 5117 Centre Avenue, Pittsburgh, PA, 15213-1863, USA.
Parise RA; Cancer Therapeutics Program, UPMC Hillman Cancer Center, Hillman Research Pavilion, Room G27E 5117 Centre Avenue, Pittsburgh, PA, 15213-1863, USA.
Miller BM; Investigational Drug Service, UPMC Cancer Centers, Pittsburgh, PA, USA.
Ivy SP; Investigational Drug Branch, Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, USA.
Chu E; Cancer Therapeutics Program, UPMC Hillman Cancer Center, Hillman Research Pavilion, Room G27E 5117 Centre Avenue, Pittsburgh, PA, 15213-1863, USA.; Division of Hematology-Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Venkataramanan R; Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, PA, USA.
Beumer JH; Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, PA, USA. .; Cancer Therapeutics Program, UPMC Hillman Cancer Center, Hillman Research Pavilion, Room G27E 5117 Centre Avenue, Pittsburgh, PA, 15213-1863, USA. .; Division of Hematology-Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA. .
Pokaż więcej
Źródło :
Cancer chemotherapy and pharmacology [Cancer Chemother Pharmacol] 2020 Oct; Vol. 86 (4), pp. 535-545. Date of Electronic Publication: 2020 Sep 18.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural
MeSH Terms :
Antineoplastic Combined Chemotherapy Protocols/*pharmacokinetics
Carboplatin/*pharmacokinetics
Contrast Media/*pharmacokinetics
Iohexol/*pharmacokinetics
Administration, Intravenous ; Animals ; Antineoplastic Combined Chemotherapy Protocols/administration & dosage ; Area Under Curve ; Bone Marrow/chemistry ; Carboplatin/administration & dosage ; Contrast Media/administration & dosage ; Creatinine ; Cytochrome P-450 Enzyme System/metabolism ; Deoxycytidine/administration & dosage ; Deoxycytidine/analogs & derivatives ; Deoxycytidine/pharmacokinetics ; Drug Dosage Calculations ; Drug Interactions ; Female ; Glomerular Filtration Rate ; Glucuronosyltransferase/metabolism ; Humans ; Iohexol/administration & dosage ; Kidney/chemistry ; Kidney/metabolism ; Metabolic Clearance Rate ; Mice ; Microsomes, Liver ; Models, Animal ; Paclitaxel/administration & dosage ; Paclitaxel/pharmacokinetics ; Specific Pathogen-Free Organisms ; Tandem Mass Spectrometry ; Tissue Distribution
Czasopismo naukowe
Tytuł :
Patient-related Risk Factors for Nausea and Vomiting With Standard Antiemetics in Patients With Cancer Receiving Carboplatin: A Retrospective Study.
Autorzy :
Nasu I; Department of Pharmacy, Toranomon Hospital, Tokyo, Japan; Division of Pharmaceutical Care Sciences, Keio University Graduate School of Pharmaceutical Sciences, Tokyo, Japan. Electronic address: .
Shimano R; Department of Pharmacy, Toranomon Hospital, Tokyo, Japan.
Kawazoe H; Division of Pharmaceutical Care Sciences, Keio University Graduate School of Pharmaceutical Sciences, Tokyo, Japan; Division of Pharmaceutical Care Sciences, Center for Social Pharmacy and Pharmaceutical Care Sciences, Keio University Faculty of Pharmacy, Tokyo, Japan.
Nakamura T; Division of Pharmaceutical Care Sciences, Keio University Graduate School of Pharmaceutical Sciences, Tokyo, Japan; Division of Pharmaceutical Care Sciences, Center for Social Pharmacy and Pharmaceutical Care Sciences, Keio University Faculty of Pharmacy, Tokyo, Japan.
Miura Y; Department of Medical Oncology, Toranomon Hospital, Tokyo, Japan.
Takano T; Department of Medical Oncology, Toranomon Hospital, Tokyo, Japan.
Hayashi M; Department of Pharmacy, Toranomon Hospital, Tokyo, Japan.
Pokaż więcej
Źródło :
Clinical therapeutics [Clin Ther] 2020 Oct; Vol. 42 (10), pp. 1975-1982. Date of Electronic Publication: 2020 Aug 28.
Typ publikacji :
Journal Article; Observational Study
MeSH Terms :
Antiemetics/*therapeutic use
Carboplatin/*adverse effects
Nausea/*chemically induced
Vomiting/*chemically induced
Aged ; Carboplatin/administration & dosage ; Dexamethasone/administration & dosage ; Female ; Humans ; Male ; Middle Aged ; Neoplasms/drug therapy ; Retrospective Studies ; Risk Factors
Czasopismo naukowe
Tytuł :
Comparative Study of the Mode of Action of Clinically Approved Platinum-Based Chemotherapeutics.
Autorzy :
Schoch S; Department of Food Chemistry and Toxicology, Karlsruhe Institute of Technology, Adenauerring 20a, 76131 Karlsruhe, Germany.; Department of Laboratory Medicine, Lund University, Scheelevägen 2, 22381 Lund, Sweden.
Gajewski S; Department of Food Chemistry and Toxicology, Karlsruhe Institute of Technology, Adenauerring 20a, 76131 Karlsruhe, Germany.
Rothfuß J; Department of Food Chemistry and Toxicology, Karlsruhe Institute of Technology, Adenauerring 20a, 76131 Karlsruhe, Germany.
Hartwig A; Department of Food Chemistry and Toxicology, Karlsruhe Institute of Technology, Adenauerring 20a, 76131 Karlsruhe, Germany.
Köberle B; Department of Food Chemistry and Toxicology, Karlsruhe Institute of Technology, Adenauerring 20a, 76131 Karlsruhe, Germany.
Pokaż więcej
Źródło :
International journal of molecular sciences [Int J Mol Sci] 2020 Sep 21; Vol. 21 (18). Date of Electronic Publication: 2020 Sep 21.
Typ publikacji :
Comparative Study; Journal Article
MeSH Terms :
Carboplatin*/pharmacokinetics
Carboplatin*/pharmacology
Cisplatin*/pharmacokinetics
Cisplatin*/pharmacology
Neoplasms*/drug therapy
Neoplasms*/metabolism
Neoplasms*/pathology
Oxaliplatin*/pharmacokinetics
Oxaliplatin*/pharmacology
Apoptosis/drug effects ; Cell Line, Tumor ; DNA Repair/drug effects ; DNA, Neoplasm/metabolism ; Humans
Czasopismo naukowe
Tytuł :
Suppressive effect upon carboplatin hypersensitivity reaction via pegylated liposomal doxorubicin combination therapy.
Autorzy :
Shimada K; Department of Gynecologic Oncology, Hyogo Cancer Center, 13-70 Kitaoji-cho, Akashi-city, Hyogo, 673-8558, Japan.
Nagao S; Department of Gynecologic Oncology, Hyogo Cancer Center, 13-70 Kitaoji-cho, Akashi-city, Hyogo, 673-8558, Japan. .
Suzuki K; Department of Gynecologic Oncology, Hyogo Cancer Center, 13-70 Kitaoji-cho, Akashi-city, Hyogo, 673-8558, Japan.
Shibutani T; Department of Gynecologic Oncology, Hyogo Cancer Center, 13-70 Kitaoji-cho, Akashi-city, Hyogo, 673-8558, Japan.
Yamamoto K; Department of Gynecologic Oncology, Hyogo Cancer Center, 13-70 Kitaoji-cho, Akashi-city, Hyogo, 673-8558, Japan.
Jimi T; Department of Gynecologic Oncology, Hyogo Cancer Center, 13-70 Kitaoji-cho, Akashi-city, Hyogo, 673-8558, Japan.
Yano H; Department of Gynecologic Oncology, Hyogo Cancer Center, 13-70 Kitaoji-cho, Akashi-city, Hyogo, 673-8558, Japan.
Kitai M; Department of Gynecologic Oncology, Hyogo Cancer Center, 13-70 Kitaoji-cho, Akashi-city, Hyogo, 673-8558, Japan.
Shiozaki T; Department of Gynecologic Oncology, Hyogo Cancer Center, 13-70 Kitaoji-cho, Akashi-city, Hyogo, 673-8558, Japan.
Yamaguchi S; Department of Gynecologic Oncology, Hyogo Cancer Center, 13-70 Kitaoji-cho, Akashi-city, Hyogo, 673-8558, Japan.
Pokaż więcej
Źródło :
International journal of clinical oncology [Int J Clin Oncol] 2020 Sep; Vol. 25 (9), pp. 1718-1725. Date of Electronic Publication: 2020 May 23.
Typ publikacji :
Journal Article
MeSH Terms :
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Carboplatin/*adverse effects
Fallopian Tube Neoplasms/*drug therapy
Ovarian Neoplasms/*drug therapy
Peritoneal Neoplasms/*drug therapy
Adult ; Aged ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Carboplatin/administration & dosage ; Doxorubicin/administration & dosage ; Doxorubicin/analogs & derivatives ; Fallopian Tube Neoplasms/mortality ; Female ; Humans ; Middle Aged ; Neoplasm Recurrence, Local/drug therapy ; Neoplasm Recurrence, Local/mortality ; Peritoneal Neoplasms/mortality ; Polyethylene Glycols/administration & dosage ; Young Adult
Czasopismo naukowe
Tytuł :
Phase II trial of carboplatin and bevacizumab in patients with breast cancer brain metastases.
Autorzy :
Leone JP; Dana-Farber Cancer Institute, Dana-Farber/Brigham & Women's Cancer Center, 450 Brookline Avenue, Boston, MA, 02215, USA.
Emblem KE; Department of Diagnostic Physics, Oslo University Hospital, Oslo, Norway.
Weitz M; Dana-Farber Cancer Institute, Dana-Farber/Brigham & Women's Cancer Center, 450 Brookline Avenue, Boston, MA, 02215, USA.
Gelman RS; Dana-Farber Cancer Institute, Dana-Farber/Brigham & Women's Cancer Center, 450 Brookline Avenue, Boston, MA, 02215, USA.
Schneider BP; Indiana University School of Medicine, Indianapolis, IN, USA.
Freedman RA; Dana-Farber Cancer Institute, Dana-Farber/Brigham & Women's Cancer Center, 450 Brookline Avenue, Boston, MA, 02215, USA.
Younger J; Massachusetts General Hospital, Boston, MA, USA.
Pinho MC; University of Texas Southwestern Medical Center, Dallas, TX, USA.
Sorensen AG; IMRIS Inc., Minnetonka, MN, USA.
Gerstner ER; Massachusetts General Hospital, Boston, MA, USA.
Harris G; Massachusetts General Hospital, Boston, MA, USA.
Krop IE; Dana-Farber Cancer Institute, Dana-Farber/Brigham & Women's Cancer Center, 450 Brookline Avenue, Boston, MA, 02215, USA.
Morganstern D; Dana-Farber Cancer Institute, Dana-Farber/Brigham & Women's Cancer Center, 450 Brookline Avenue, Boston, MA, 02215, USA.
Sohl J; Dana-Farber Cancer Institute, Dana-Farber/Brigham & Women's Cancer Center, 450 Brookline Avenue, Boston, MA, 02215, USA.
Hu J; Dana-Farber Cancer Institute, Dana-Farber/Brigham & Women's Cancer Center, 450 Brookline Avenue, Boston, MA, 02215, USA.
Kasparian E; Dana-Farber Cancer Institute, Dana-Farber/Brigham & Women's Cancer Center, 450 Brookline Avenue, Boston, MA, 02215, USA.
Winer EP; Dana-Farber Cancer Institute, Dana-Farber/Brigham & Women's Cancer Center, 450 Brookline Avenue, Boston, MA, 02215, USA.
Lin NU; Dana-Farber Cancer Institute, Dana-Farber/Brigham & Women's Cancer Center, 450 Brookline Avenue, Boston, MA, 02215, USA. .
Pokaż więcej
Źródło :
Breast cancer research : BCR [Breast Cancer Res] 2020 Nov 30; Vol. 22 (1), pp. 131. Date of Electronic Publication: 2020 Nov 30.
Typ publikacji :
Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Antineoplastic Combined Chemotherapy Protocols/*administration & dosage
Bevacizumab/*administration & dosage
Brain Neoplasms/*drug therapy
Breast Neoplasms/*drug therapy
Carboplatin/*administration & dosage
Adult ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Bevacizumab/adverse effects ; Brain/diagnostic imaging ; Brain/pathology ; Brain Neoplasms/genetics ; Brain Neoplasms/mortality ; Brain Neoplasms/secondary ; Breast/pathology ; Breast Neoplasms/genetics ; Breast Neoplasms/mortality ; Breast Neoplasms/pathology ; Carboplatin/adverse effects ; Female ; Genotyping Techniques ; Humans ; Kaplan-Meier Estimate ; Magnetic Resonance Imaging ; Middle Aged ; Polymorphism, Single Nucleotide ; Progression-Free Survival ; Trastuzumab/administration & dosage ; Trastuzumab/adverse effects ; Vascular Endothelial Growth Factor A/genetics
Czasopismo naukowe
Tytuł :
Evaluation of bioabsorbable calcium sulfate hemihydrate beads for local delivery of carboplatin.
Autorzy :
Traverson M; Department of Clinical Sciences, College of Veterinary Medicine, North Carolina State University, Raleigh, North Carolina, United States of America.
Stewart CE; Department of Biological Sciences, College of Sciences, North Carolina State University, Raleigh, North Carolina, United States of America.
Papich MG; Department of Molecular Biomedical Sciences, College of Veterinary Medicine, North Carolina State University, Raleigh, North Carolina, United States of America.
Pokaż więcej
Źródło :
PloS one [PLoS One] 2020 Nov 05; Vol. 15 (11), pp. e0241718. Date of Electronic Publication: 2020 Nov 05 (Print Publication: 2020).
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Calcium Sulfate/*chemistry
Carboplatin/*pharmacology
Neoplasms/*veterinary
Absorbable Implants ; Animals ; Carboplatin/chemistry ; Cats ; Cell Line, Tumor ; Cell Proliferation/drug effects ; Cell Survival/drug effects ; Chromatography, High Pressure Liquid ; Dogs ; Microspheres ; Neoplasms/drug therapy ; Particle Size ; Pilot Projects ; Veterinary Medicine
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies